| Performance Pharmatech Ltd. |
| Registered number: |
06775451 |
| Balance Sheet |
| as at 31 December 2020 |
|
|
|
|
2020 |
|
|
2019 |
| £ |
£ |
|
| Fixed assets |
|
|
|
1,261 |
|
|
973 |
| Current assets |
|
|
227,038 |
|
|
226,016 |
| Prepayments and accrued income |
|
|
621 |
|
|
694 |
|
|
|
227,659 |
|
|
226,710 |
| Creditors: amounts falling due within one year |
|
|
(15,387) |
|
|
(8,298) |
| Net current assets |
|
|
|
212,272 |
|
|
218,412 |
| Total assets less current liabilities |
|
|
|
213,533 |
|
|
219,385 |
| Accruals and deferred income |
|
|
|
(575) |
|
|
(575) |
| Net assets |
|
|
|
212,958 |
|
|
218,810 |
|
|
|
|
|
|
|
|
| Capital and reserves |
|
|
|
212,958 |
|
|
218,810 |
|
|
|
|
|
|
|
|
| Number |
Number |
| Average number of employees |
|
|
|
2 |
|
|
2 |
|
|
|
|
|
|
|
|
| Other creditors includes a loan from the directors to the company of £400 (2019 £300). During the year the company paid rent of £600 (2019 £600) to the directors for use of home office space. |
| The company is a private company limited by shares and incorporated in England. Its registered office is 10 Wellington Street, Cambridge, CB1 1HW. |
| The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006. |
| The members have not required the company to obtain an audit in accordance with section 476 of the Act. |
| The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. |
| The accounts have been prepared in accordance with the micro entity provisions of the Companies Act 2006 and FRS 105, The Financial Reporting Standard applicable to the Micro-entities Regime. The accounts have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies. |
|
|
|
|
| Paul Osborne |
| Director |
| Approved by the board on 8 February 2021 |
